Riding the Wave of the Future: How Modularity Can Help Minimize Facilities Cost and Timelines
From a business perspective, modularity must provide a substantial business benefit to be deemed an appropriate solution. Modularity is of significant value in biomanufacturing capital investment programs for several reasons; most notably for a higher predictability of a successful project outcome. Owners and Project Managers are seeking holistic solutions that provide benefits in driving cost control and a rapid delivery - a modular solution provides an efficient execution strategy to meet this goal. With a fully integrated and modular approach, time to market is increased significantly, since modular solutions can be delivered in 9- to 12-months; versus 18- to 30-months for a conventional delivery method. Reaching the market quicker provides more manufacturing capacity, which in turn directly benefits the net present value (NPV).
Speakers:
George WikerV.P. Life Sciences & Chemicals – Market Segment Lead
M+W U.S., Inc., A Company of the M+W Group
George, a successful architect and businessman for more than 22-years, fosters the belief that clients want consultants and designers to genuinely focus on helping them solve problems. This belief enables him to lead successful project teams worldwide in the development of cGMP/GMP manufacturing facilities and operations for pharmaceutical and consumer product companies. His working history and experience provides an environment of integrated design solutions in an effective, aesthetic, and operational manner. Through his leadership project teams explore new and innovative project solutions, and objectively apply them when it makes the most sense for a project; helping clients succeed by providing high quality, constructible, and compliant solutions. One such solution is SmartFit – a modular based system that is fully customizable to a client’s need. George is a contributing author and lecturer, providing insight, trends, ideas, and concepts to user groups and industry professionals.
Maik Jornitz
President
G-CON Manufacturing, Inc
Mr. Jornitz is a distinguished technical expert with close to 30 years of experience in bioprocesses, especially sterilizing grade filtration and single-use technologies, including regulatory requirements, integrity testing, systems design, and optimization. Jornitz has published multiple books, book chapters and over 100 scientific papers. He is a member of the PDA Science Advisory Board and Audit Committee, as well as an advisory board member of Artemes Technologies, Biotechnology Industry Council and multiple scientific publciations. He received his M.Eng. in Bioengineering at the University of Applied Sciences in Hamburg, Germany and accomplished the PED program at IMD Business School in Lausanne, Switzerland.